AUTHOREA
Log in Sign Up Browse Preprints
Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

May 11, 2020
Are multiple sclerosis therapies safe in SARS-Cov-2 times?
Francesco Ferrara, Giovanni Granata, Chiara Pelliccia, et al.
May 13, 2020
Active agents of Renin Angiotensin System and SARS-CoV-2
Antonio Vitiello, Raffaele La Porta, Giovanni Granata, et al.
May 11, 2020
Plasma Therapy in the fight against Sars-CoV-2: what boils in the pot.
Antonio Vitiello, Francesco Ferrara, Raffaele La Porta, et al.
May 06, 2020
Clinical and phamacological analysis of Sars Cov 2: how combination therapy makes che...
Francesco Ferrara, Giovanni Granata, Chiara Pelliccia, et al.
April 29, 2020
Clinical pharmacology aspects in patients treated with TNF inhibitors during SARS-Cov...
Antonio Vitiello, Chiara Pelliccia, Francesco Ferrara, et al.
April 27, 2020
The added value of pirfenidone to declare war on inflammation and the fibrotic state...
Francesco Ferrara, Giovanni Granata, Chiara Pelliccia, et al.
April 27, 2020
Patient management positive covid: the central role of clinical nutrition and supplem...
Francesco Ferrara, Giovanni Granata, Chiara Pelliccia, et al.
April 23, 2020
What do we know about the correlation between RAS and SARS-Cov-2 infection?
Antonio Vitiello, Raffaele La Porta, Giovanni Granata, et al.
April 23, 2020
Current treatments and scientific advancements to combat the epidemic novel coronavir...
Francesco Ferrara, Chiara Pelliccia, Antonio Vitiello, et al.
April 23, 2020
Anti-rheumatic in SARS Cov 2: benefit or risk?
Francesco Ferrara, Chiara Pelliccia, Antonio Vitiello, et al.